Intro

This chapter features a detailed discussion on the Navigator trial, which investigates innovative treatments for non-allergic asthma. The speakers emphasize the significance of tezapelumab, a monoclonal antibody, and connect the conversation to earlier episodes about advancements in asthma therapy.